489 / 1778
Stage I ‘medium risk ‘ (n=527)
VBT
EBRT+VBT
Vaginal recurrence
(crude)
2.7%
1.9%
Locoregional
5.0%
1.5%
Overall Survival
90%
89%
Toxicity Gr 3: GI
0%
2%
vagina 0.8%
0%
➢
Similar QoL results favoring VBT alone
Sorbe et al, IJROBP 2012 + Int J Gynecol Cancer 2012
Swedish randomised trial (1997-2008)